- Home
- COLL vs CHY Comparison
COLL vs CHY Comparison
Compare COLL & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- CHY
- Stock Information
- Founded
- COLL 2002
- CHY 2003
- Country
- COLL United States
- CHY United States
- Employees
- COLL N/A
- CHY N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- CHY Investment Managers
- Sector
- COLL Health Care
- CHY Finance
- Exchange
- COLL Nasdaq
- CHY Nasdaq
- Market Cap
- COLL 910.2M
- CHY 934.9M
- IPO Year
- COLL 2015
- CHY N/A
- Fundamental
- Price
- COLL $28.07
- CHY $9.41
- Analyst Decision
- COLL Strong Buy
- CHY
- Analyst Count
- COLL 5
- CHY 0
- Target Price
- COLL $43.60
- CHY N/A
- AVG Volume (30 Days)
- COLL 438.9K
- CHY 128.3K
- Earning Date
- COLL 05-08-2025
- CHY 01-01-0001
- Dividend Yield
- COLL N/A
- CHY 10.11%
- EPS Growth
- COLL 43.56
- CHY N/A
- EPS
- COLL 1.86
- CHY N/A
- Revenue
- COLL $631,449,000.00
- CHY N/A
- Revenue This Year
- COLL $20.00
- CHY N/A
- Revenue Next Year
- COLL $3.93
- CHY N/A
- P/E Ratio
- COLL $15.63
- CHY N/A
- Revenue Growth
- COLL 11.41
- CHY N/A
- 52 Week Low
- COLL $27.28
- CHY $9.97
- 52 Week High
- COLL $42.29
- CHY $12.16
- Technical
- Relative Strength Index (RSI)
- COLL 37.90
- CHY 26.66
- Support Level
- COLL $29.01
- CHY $9.93
- Resistance Level
- COLL $30.53
- CHY $10.27
- Average True Range (ATR)
- COLL 0.82
- CHY 0.17
- MACD
- COLL -0.10
- CHY -0.03
- Stochastic Oscillator
- COLL 5.73
- CHY 13.58
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.